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Introduction: Combination inhaled corticosteroid/long-acting bronchodilator (ICS/LABA) ther-
apy reduces the exacerbation rate and improves spirometry and quality of life in COPD. We hy-
pothesized that ICS/LABA therapy also improves small airway function measured by FOT.
Methods: 14 subjects with COPD were commenced on combination fluticasone propionate/sal-
meterol therapy for 3 months. At baseline, subjects completed the St George Respiratory
Questionnaire (SGRQ) and underwent standard pulmonary function tests as well as forced
oscillation technique (FOT) and single and multiple breath nitrogen washouts. All tests were
repeated at the completion of 3 months of therapy.
Results: Subjects were of mean (SD) age 65.9 years (8.4), BMI 30.0 (5.6), pack years 51.4
(21.1), post-bronchodilator FEV1% predicted 62.7 (20). At baseline, mean SGRQ total was
39.0 (17.7) and FRC% predicted 125.4 (31.3). From FOT, Rrs-total was 5.69 (1.29) cmH2O/L/
s, Xrs-total 3.48 (2.16) cmH2O/L/s, EFL Index 3.51 (2.45) cmH2O/L/s. After 3 months of ther-
apy, there were significant improvements in SGRQ score (13.81, p < 0.0001) despite no
change in FEV1 (þ40 mL, p Z 0.14). From FOT, total resistance (0.63 cmH2O/L/s,
p Z 0.0004), reactance (þ1.2 cmH2O/L/s, p Z 0.013), and expiratory flow limitationwas conducted at Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia.
iology and Imaging Group, The Woolcock Institute of Medical Research, PO Box M77, Missenden Rd,
l.: þ61 413536767; fax: þ61 2 9114 0014.
.usyd.edu.au, sophtimmins@yahoo.com.au (S.C. Timmins), chantale@woolcock.org.au (C. Diba),
(R.E. Schoeffel), cms@woolcock.org.au (C.M. Salome), ggk@woolcock.org.au (G.G. King), cindy.
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CC/TLC% closing capacity/t
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LABA long-acting beta-ago(1.21 cmH2O/L/s, p Z 0.02) also improved. There were no significant changes in ventilation
heterogeneity indices.
Conclusion: Combination therapy is associated with improvements in small airways function in
COPD, despite an absence of change in FEV1. FOT may be a clinically useful marker of small
airway function in COPD that is responsive to treatment.
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Chronic Obstructive Pulmonary Disease (COPD) is associ-
ated with significant morbidity, mortality, and economic
burden. International guidelines recommend prescription
of long-acting bronchodilators (long-acting beta-agonists
(LABA) or muscarinic antagonists (LAMA)) for symptomatic
COPD patients with moderate airflow obstruction [1],
while inhaled corticosteroids (ICS) are recommended
when the FEV1 is less than 50% of predicted and acute
exacerbations are present [1]. ICS/LABA combination
treatment improves symptoms, quality of life, and exac-
erbation rate [2e4] as well as physiological measures such
as spirometry, inspiratory capacity (IC) and dynamic hy-
perinflation [5,6]. Treatment responses in terms of more
detailed physiological measures such as airway resistance
and nitrogen washout have not been assessed. These are
advantageous and may add complementary information
since they generally represent lung function during normal
tidal breathing.
Forced oscillation technique (FOT) is an effort-
independent method for measuring lung mechanics. The
FOT parameters of resistance (Rrs) and reactance (Xrs)
are indices of airway calibre and of the elastic properties
of the respiratory system, respectively, and reflect both
small and large airway properties. Xrs is sensitive and
specific to the presence of expiratory flow limitation
(EFL) in COPD [7] and to change during recovery from
acute exacerbations of COPD [8]. Rrs and Xrs are also
sensitive to changes following bronchodilator inhalationin COPD [9,10]. Although Rrs and Xrs improve in asth-
matic subjects following ICS and ICS/LABA combination
therapy [11,12], there are no comparable studies in
COPD.
The nitrogen washout tests provide indices of airway
closure and heterogeneity in ventilation distribution. A
single breath nitrogen washout (SBNW) measures closing
volume (CV) and the phase III slope, which correlate
with small airway pathology in smokers [13]. There is
evidence that CV reflects small airway dysfunction in
COPD that is due to inflammation and remodelling,
separately from the effects of reduced parenchymal
support due to emphysema [14] The multiple breath
nitrogen washout (MBNW) allows partitioning of venti-
lation distribution into the convection dependent air-
ways (Scond) and convection-diffusion dependent
airways (Sacin) [15]. The MBNW parameters are sensitive
to early small airways disease in smokers [16] but do not
change in response to bronchodilator administration in
severe COPD [17].
In this study, we aimed to determine and interpret
changes in small airway function measured by FOT during
ICS/LABA treatment in COPD over a 3-month period. We
measured changes in Rrs, Xrs and EFL derived from FOT; in
closing capacity (CC) and phase III slope from SBNW; and
in Scond and Sacin from MBNW. We hypothesized that
significant improvements in FOT variables would occur
following the commencement of therapy in the absence
of significant change in spirometry or ventilation
heterogeneity.
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Subject characteristics
Subjects were recruited from a volunteer database at Royal
North Shore Hospital and advertisements in a local news-
paper. Inclusion criteria were age 40 years or older, a
physician diagnosis of COPD, smoking history of greater
than 10 pack years, post-bronchodilator FEV1/FVC <0.7, no
regular inhaled steroid use in the past 3 months and
symptoms of shortness of breath on exertion or chronic
cough for at least 12 months. Subjects were excluded if
they had a coexistent diagnosis of asthma or other respi-
ratory disease, or an exacerbation of COPD within the last 6
weeks defined as an increase in COPD symptoms for 3 or
more days that necessitated an increase in treatment.
Written informed consent was obtained from each subject
prior to enrolment. The experimental protocol was
approved by the Hawkesbury/Harbour Human Research
Ethics Committee of Northern Sydney Central Coast Health
(0903-050M).
Study design
This was a longitudinal, open label, observation study of
inhaled fluticasone/salmeterol treatment in COPD over 3
months. Combination fluticasone/salmeterol 250/25 mg
(Seretide Metered Dose Inhaler, GlaxoSmithKline) 2 puffs
twice daily through an E-Chamber 500 mL Spacer (Bird
Healthcare) was commenced the next day after their first
visit. Subjects attended a total of 4 visits; at the start of the
study and every month for 3 months. The dose counters of
the fluticasone/salmeterol inhalers were noted at each visit
to provide an indication of adherence. Subjects did not
withhold their usual COPD medication prior to all testing.
At the first visit, subjects completed a questionnaire
about respiratory symptoms, medication use, and smoking
history. Health related quality of life was assessed using the
St George’s Respiratory Questionnaire (SGRQ) with a 3-
month recall period [18]. Baseline dyspnoea index (BDI) was
also calculated [19]. Lung function tests were performed in
the following order: FOT, spirometry, diffusing capacity,
SBNW, MBNW, and lung volume measurements by body
plethysmography. Subjects then performed post-
bronchodilator spirometry 15 min after 400 mcg of
inhaled salbutamol. Subjects completed FOT and spirom-
etry only at the 1- and 2-month visits. At the end of 3
months’ of treatment, subjects repeated the baseline tests
in the same order. SGRQ was again completed, and change
in dyspnoea was assessed by the transitional dyspnoea
index (TDI) [19].
Forced oscillation technique (FOT)
Respiratory system resistance (Rrs) and reactance (Xrs)
were measured at an oscillation frequency of 6 Hz. The
FOT device was developed in house [20] and conforms to
the general design and specifications for FOT machines
[21]. Oscillations were generated by a loudspeaker with
flow and pressure measured at the airway opening by a
screen pneumotachograph and solid-state pressuretransducer. Three separate measurements were made
during tidal breathing for 60 s. Data were processed using
a complete breath method where breaths with extreme
and negative Rrs values or artifacts were excluded from
any subsequent processing [22]. After processing, the
mean Rrs or Xrs value within the whole breath (Rrs-total
and Xrs-total) as well as those corresponding to the
inspiratory component only (Rrs-insp and Xrs-insp) were
calculated over all included breaths. The Rrs-insp and Xrs-
insp are theoretically measurements of respiratory me-
chanics that are unaffected by the presence of expiratory
flow limitation [7]. Predicted values for Rrs and Xrs were
those of Brown et al. [23].
To assess expiratory flow limitation, the EFL Index was
calculated as the mean difference between the mean
inspiratory (Xrs-insp) and expiratory (Xrs-exp) reactance
values of each breath [7]. Although a threshold value of
>2.8 cmH2O/L/s was shown to indicate the presence of
expiratory flow limitation in COPD, the index was treated as
a continuous variable in data analyses.
Spirometry, body plethysmography, and diffusing
capacity
Spirometry and diffusing capacity were performed accord-
ing to American Thoracic Society/European Respiratory
Society using a Medgraphics system (MedGraphics Ultima
Series, Medical Graphics Corporation Minnesota USA)
[24,25]. Lung volumes were measured by body plethys-
mography using a Sensormedics Vmax BodyBox (Sensor-
medics Corporation, Yorba Linda, CA, USA). Results are
reported as absolute and percent of predicted values
[26e28].
Single breath nitrogen washout (SBNW)
Closing volume (CV) and slope of phase III were measured
using the same Medgraphics system. Pure oxygen was
inhaled at a flow rate <50 L/min from residual volume (RV)
to total lung capacity (TLC), followed by exhalation at a
flow rate of 30 L/min from TLC to RV. A plot of exhaled N2
concentration versus lung volume was used to calculate the
alveolar slope (slope of phase III) and closing volume, CV.
Closing capacity (sum of CV and plethysmographic RV) was
calculated as a fraction of plethysmographic total lung
capacity (CC/TLC).
Multiple breath nitrogen washout (MBNW)
Ventilation heterogeneity was measured by the multiple
breath nitrogen washout as previously described [29].
Briefly, a closed-circuit, bag-in-box breathing system was
used to deliver 100% oxygen, which subjects breathed at a
tidal volume of 1.0e1.3 L, at a respiratory frequency of
9e12 breaths/min, until end-tidal nitrogen concentration
was 1/40th of the starting alveolar nitrogen concentration.
The indices of ventilation heterogeneity determined pre-
dominantly by convection dependent (Scond) and by
diffusion-convection dependent (Sacin) mechanisms were
derived as previously described [15].
Table 2 Baseline and 3 month results of small airways
function, hyperinflation, and quality of life.
Baseline 3 months p Value
FEV1 (L) 1.67 (0.57) 1.71 (0.57) 0.57
FVC (L) 3.13 (0.82) 3.13 (0.7) 0.99
FEF25e75 (L/s) 0.75 (0.41) 0.86 (0.52) 0.14
Rrs-total
(cmH20/L/s)
5.685 (1.29) 5.052 (1.24) 0.0004
Xrs-total
(cmH20/L/s)
L3.477 (2.16) L2.451 (1.31) 0.0129
EFL Index
(cmH20/L/s)
3.508 (2.45) 2.295 (1.52) 0.0173
Rrs-insp
(cmH20/L/s)
4.788 (1.19) 4.280 (1.05) 0.0058
Xrs-insp
(cmH20/L/s)
L1.394 (0.64) L1.094 (0.46) 0.0188
Sacin (n 13) L1 0.365 (0.09) 0.378 (0.1) 0.62
Scond (n 13) L1 0.043 (0.02) 0.046 (0.03) 0.38a
Phase III slope% 791.79 808.38 0.54
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Statistical analyses was performed using Analyse-it for
Excel (Analyse-It Software Ltd, Leeds, England) and IBM(R)
SPSS(R) Statistics version 20.0 (Armonk, NY, USA). Data are
presented as means with standard deviations (SD) unless
otherwise specified. p Values of <0.05 were considered
statistically significant. ShapiroeWilk test was used to
assess normality of data variables.
Changes in small airways function
Changes in FOT variables from baseline over 3 months
treatment were examined using a 1-way repeated measures
analysis of variance (ANOVA). Dunnett’s posthoc test was
used to assess pairwise differences between individual
visits.
Changes in spirometry, FRC, MBNW variables, SBNW
variables, and SGRQ from baseline to 3 months were
compared using paired t test for parametric variables and
Wilcoxon test for nonparametric variables.predicted (333.22) (152.52)
CC/TLC% 62.85 (9.15) 61.03 (7.92) 0.28
SGRQ (n 13) 36.77 (15.1) 27.22 (13.7) 0.0007
FRC pleth (L) 4.04 (1.28) 3.78 (1.16) 0.0054
The parameters in bold represent the underwent significant
change over the study period.
a Wilcoxon test.Results
14 COPD subjects completed 12 weeks of combination
therapy. The baseline demographic characteristics and
lung function data of the study subjects are provided in
Table 1. Overall, the subjects had moderate airflow
obstruction, a mild increase in resistance, and severely
abnormal reactance values. Seven of the 14 subjects had
an EFL Index >2.8 cmH2O/L/s, a previously used cut-off
for presence of expiratory flow limitation [7]. 6 subjects
were hyperinflated at baseline, as assessed by FRC. 8
subjects were on no medication, while 6 subjects were
taking LAMA therapy. 12 subjects were ICS naı¨ve, while 2
had tried ICS more than 1 year ago. The impairment of
quality of life, measured by SGRQ, across the group was
fairly mild, although there was a broad range of impact
(9.83e74.49). At baseline, SGRQ total score correlated
with Scond (r-0.62, p0.02) and SGRQ impact score corre-
lated with Scond (r-0.61, p0.02) and Sacin (rs 0.53, p
0.05).Table 1 Baseline demographic data of the study group.
Mean (SD)
Age 65.9 (8.4)
BMI (kg/m2) 30.0 (5.6)
Pack years 51.4 (21.1)
SGRQ 39.0 (17.7)
BDI 7.23 (1.24)
FEV1 post-bronchodilator% predicted 62.7 (20)
FEV1/FVC post-bronchodilator 57.8 (11.6)
Xrs-total% predicted 673.6 (338.5)
Rrs-total% predicted 170.9 (46.0)
DLCO (mL CO/min/mmHg) 61.3 (15.7)
FRC% predicted 116.4 (27.8)
LAMA 8
Smoking 2Small airway measurements
Table 2 contains the baseline and end of study measure-
ments of small airways function. Significant improvements
were seen in all FOT parameters: Rrs-total, Xrs-total, EFL
Index, Rrs-insp, and Xrs-insp. No significant changes in
ventilation heterogeneity or closure were identified. Like-
wise, no significant change in the spirometric parameters
was seen. From the ANOVA, no significant differences were
seen for Rrs-total (p Z 0.332) and Rrs-insp (p Z 0.51).
Significant differences between the 4 study visits were seen
for Xrs-insp (p Z 0.025), Xrs-total (p Z 0.003), and EFL
Index (p Z 0.002).
The mean FOT parameters at each of the 4 study visits
are displayed in Fig. 1(a)e(e). No significant differences
could be seen at any of the study visits in comparison to
visit 1 for Rrs-total or Rrs-insp. In comparison to visit 1,
significant changes could be seen in Xrs-total at visit 2
(p Z 0.02), visit 3 (p Z 0.06), and visit 4 (p Z 0.09).
Significant differences in Xrs-insp compared to visit 1
could be seen at visit 2 (pZ 0.015) and visit 4 (pZ 0.032)
but not visit 3 (p Z 0.232). In comparison to visit 1, sig-
nificant differences in EFL Index could be seen at each
study visit: visit 2 (p Z 0.002), visit 3 (p Z 0.002), visit 4
(p Z 0.014).
Quality of life, dyspnoea, and hyperinflation
Quality of life assessed by SGRQ (n Z 13) improved signif-
icantly from 39.85 (18.16) at baseline to 27.22 (13.67) at
the completion of the study (mean difference 12.63 (7.91),
p < 0.0001). There was a significant change in dyspnoea as
Figure 1 Changes in FOT parameters: (a) total respiratory resistance (Rrs-total), (b) inspiratory respiratory resistance (Rrs-insp),
(c) total respiratory reactance (Xrs-total), (d) inspiratory respiratory reactance (Xrs-insp), and (e) expiratory flow limitation index,
over the course of the study. Symbols and error bars indicate mean and standard deviation, respectively.
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plethysmograph improved significantly (0.26 L, p 0.0054),
no significant improvement was seen in IC (0.068 L, p 0.51)
or RV/TLC (1.7% p 0.165).
Discussion
Summary of findings
This small proof of concept study showed that parameters
of small airways function measured by FOT were sensitive
to modest change with therapy in COPD, in contrast to
ventilation heterogeneity, closure and spirometry. All FOT
parameters showed significant change with combination
ICS/LABA therapy. Significant changes in quality of life and
dyspnoea score also occurred after 3 months of ICS/LABA
therapy.
Comparison with other studies
While several studies have examined acute response to
bronchodilator with FOT parameters [9,30], there are no
published studies examining changes in oscillatory imped-
ance in response to therapy in COPD over months. In asth-
matics however, there are two published studies that haveconfirmed the sensitivity of impedance measured by im-
pulse oscillometry to detect changes in small airways me-
chanics in response to therapy [11,12]. Serial MBNW
measures of ventilation heterogeneity after the introduc-
tion of tiotropium in COPD subjects demonstrated that
subjects with hyperinflation had a significant increase in
pre-dose FEV1 and inspiratory capacity in the absence of
changes in ventilation heterogeneity [17]. Although we
used an alternative bronchodilator, a long-acting beta-
agonist, we also found that bronchodilation did not change
ventilation heterogeneity parameters.
In comparison to large randomized control trials of
combination therapy in COPD [2], the change in SGRQ
quality of life seen in this study was greater than expected,
however it is in keeping with results from other small
mechanistic studies [31]. The reason for the large
improvement in quality of life in our group is likely to be
multi-factorial but contributing factors would include the
education they received as part of the study regarding
COPD and their lung function, the social nature of the study
visits, as well as any treatment effects from the ICS/LABA
therapy. By the nature of study design and recruitment of
steroid naı¨ve patients, most subjects knew very little about
the nature of their disease prior to study commencement
and had the opportunity to ask questions of the study
investigator during the visits.
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therapy
LABA gives rise to smooth muscle relaxation even in the
presence of normal or increased muscle tone, which re-
sults in an increase in airway diameter and improved
airflow{Rossi, 2008 #38}. Both LABA and LAMA therapy
improve expiratory capacity by shortening the time con-
stants for lung emptying, with a resultant reduction in
end-expiratory lung volume (EELV) and increase in inspi-
ratory capacity (IC) [32e34]. These changes lead to im-
provements in exertional dyspnoea and exercise capacity
[33]. Inhaled corticosteroid therapy reduces airway
inflammation, which may in turn improve airflow by
reducing airway wall thickness [35]. Therefore, one might
expect ICS/LABA to reduce Rrs (improve airway calibre)
and improve Xrs and EFL (reduced expiratory flow
limitation).Lack of improvement with washout indices
Heterogeneity and closure were not affected by ICS/LABA
therapy in this small group. FOT at 6 Hz reflects the
contribution of both large and small airways [21], so the
improvements in the FOT parameters may be reflecting
improvement in larger airway calibre. In comparison,
ventilation heterogeneity and closure are more closely
related to peripheral airway function [13,15]. Given the
particle size of ICS/LABA therapy, it is likely that any
changes in airway calibre detected by FOT occurred pre-
dominantly in the larger airways resulting in fairly ho-
mogenous improvements in airflow, with little effect on
peripheral airway closure or ventilation heterogeneity.
EFL is very sensitive to closure so improvement in closure
measured by SBNW would be expected. CC/TLC%
improved, however this change was not statistically sig-
nificant (p 0.28). Improvement in CC alone was 0.21 L (p
0.055).Strengths and limitations of the study
As we needed to recruit COPD subjects not already taking
inhaled corticosteroids, the group overall had moderate
airflow obstruction, GOLD stage II. International guide-
lines would not recommend inhaled corticosteroids in
general for moderate airflow obstruction in the absence
of exacerbations [1]. Despite the small sample size, we
were able to detect changes in FOT where this was not
possible with the other measures. High doses of inhaled
corticosteroid were used in keeping with the TORCH study
[2]. We do not know if lower doses of inhaled cortico-
steroid or in fact single agent therapy, with either inhaled
steroid or LABA, would produce a similar effect. Our
subjects were compliant and had complete study atten-
dance, enabling us to collect detailed physiological in-
formation about small airway function, and the effects of
a commonly prescribed medication on these measures.
This is the first study to examine the effects of therapy on
small airway mechanics, ventilation heterogeneity, and
airway closure.Conclusions
In this small proof of concept study we have shown that FOT
is sensitive to modest change in small airway mechanics
with ICS/LABA combination therapy that are not detectable
with the standard outcome measure of clinical trials, FEV1.
Xrs-total, Xrs-insp, and EFL Index improved significantly
with ICS/LABA treatment. Measures of the very peripheral
small airway function, closure and ventilation heteroge-
neity, were not effected by ICS/LABA treatment. FOT has
been used to monitor recovery from acute exacerbations
[8,36] and is being evaluated as a home monitoring tool in
COPD [14,37]. The results of our study confirm another
potential use as a treatment monitoring tool, and lends
support to the incorporation of FOT into a randomized
control trial of therapy in COPD to confirm the changes we
have observed.
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